Glory Health Industry Limited has appointed Mr. Wang Shiyu as an independent non-executive director, chairman of its Internal Control Committee, and a member of its Audit Committee, effective December 1, 2025. Mr. Wang brings extensive investment banking and global M&A expertise, having participated in the restructuring, listing, and financing of over 100 enterprises since entering China’s capital markets in 1991.

Mr. Wang’s directorship term, set at three years from December 1, 2025, entitles him to an annual emolument of HK$330,000. He will hold office until the next annual general meeting and thereafter be subject to rotation and re-election in accordance with the company’s articles of association. The Board has confirmed Mr. Wang’s eligibility, stating he meets the independence criteria under the Listing Rules.

Following the resignation of a previous independent non-executive director, Glory Health Industry Limited communicated its efforts to identify a suitable candidate, including submitting an application to the Stock Exchange for waivers from certain Listing Rules, though the application was not approved. With Mr. Wang’s appointment, Glory Health Industry Limited has now fulfilled the relevant requirements of the Listing Rules regarding the number and proportion of independent non-executive directors and Audit Committee members.